Elaine Adler, Senior Venture Capital Analyst
Professional Overview
Elaine Adler is a seasoned venture capital analyst with a strong background in the biotechnology and pharmaceutical industries. She leverages her expertise in in vivo pharmacology, drug discovery, and early-stage investment to identify and support promising startups in the life sciences sector.
Experience Summary
Current Roles
Senior Venture Capital Analyst, Israel Biotech Fund (2024-09-01 to Present)
- Evaluates investment opportunities in innovative biotechnology and pharmaceutical companies
- Conducts in-depth market and competitive analyses to assess the commercial viability of startup technologies
- Collaborates with portfolio companies to provide strategic guidance and operational support
Board Member, CombinAble.AI (2024-09-01 to Present)
- Advises the leadership team on market trends, scientific developments, and investment strategies
- Leverages industry expertise to guide the company's growth and product roadmap
Board Member, TenAces Biosciences (2024-01-01 to Present)
- Provides strategic oversight and governance to the company's executive team
- Contributes to key decision-making processes and helps shape the company's long-term vision
Career Progression
Venture Capital Analyst, Israel Biotech Fund (2021-08-01 to 2024-09-01)
- Analyzed investment proposals and conducted due diligence on early-stage biotechnology companies
- Collaborated with the investment team to evaluate market opportunities and risks
- Assisted portfolio companies with business development, fundraising, and operational support
In Vivo Pharmacology Team Leader, Teva Pharmaceuticals (2018-12-01 to 2021-07-01)
- Led a team of scientists in the design, execution, and analysis of in vivo studies for novel drug candidates
- Contributed to the advancement of several product candidates through the drug development pipeline
- Communicated research findings to cross-functional stakeholders and senior management
CNS Scientist, In Vivo Team, Global R&D Group, Teva Pharmaceuticals (2017-01-01 to 2018-12-01)
- Conducted preclinical studies to assess the efficacy and safety of drug candidates targeting the central nervous system
- Collaborated with multidisciplinary teams to optimize lead compounds and inform key decision-making processes
Post-Doctorate Research Fellow, The Neurobiology of Stress Lab, Weizmann Institute of Science (2013-04-01 to 2017-01-01)
- Conducted independent research on the neurobiological mechanisms underlying stress response and resilience
- Mentored junior researchers and contributed to the publication of several peer-reviewed articles
Academic Background
Elaine Adler holds a Ph.D. in Neuroscience from the Weizmann Institute of Science, where she specialized in the neurobiology of stress. She also served as a mentor for the Institute's International Summer Science Institute, sharing her expertise with the next generation of researchers.
Areas of Expertise
- Venture capital investment in the biotechnology and pharmaceutical industries
- In vivo pharmacology and drug discovery
- Preclinical research and development
- Scientific communication and collaboration
- Team leadership and project management
Professional Impact
Elaine Adler's diverse background in both industry and academia has enabled her to provide valuable insights and support to early-stage biotechnology companies. As a senior venture capital analyst, she has played a key role in identifying and investing in promising startups, leveraging her scientific expertise to assess the viability and potential of innovative technologies. Her board memberships at CombinAble.AI and TenAces Biosciences demonstrate her commitment to guiding the growth and development of these promising organizations.
Conclusion
With her extensive experience in the life sciences industry, Elaine Adler is well-positioned to continue making a significant impact as a venture capital analyst and strategic advisor. Her deep understanding of the biotechnology and pharmaceutical sectors, combined with her strong analytical and leadership skills, make her a valuable asset to the companies and investors she collaborates with.
